Bcl-2 and p53 expression in node-negative breast carcinoma: A study with long-term follow-up

Mattia Barbareschi, Orazio Caffo, Silvio Veronese, Russel D. Leek, Paolo Fina, Steven Fox, Mariella Bonzanini, Salvatore Girlando, Luca Morelli, Claudio Eccher, Francesco Pezzella, Claudio Doglioni, Paolo Dalla Palma, Adrian Harris

Research output: Contribution to journalArticlepeer-review


Bcl-2 and p53 gene products (Bcl-2, p53) are important regulators of apoptosis and cell proliferation, and their immunohistochemical expression may help to identify high-risk breast cancer patients. The authors evaluated p53 and Bcl-2 immunoreactivity in 178 node-negative breast cancers (NNBC) with long-term follow-up (median, 60 months). Bcl-2 was seen in 111 (62%) cases, and was significantly associated with small tumor size, nonductal morphology, low tumor grade, estrogen-receptor (ER) positivity, and p53 negativity. p53 overexpression (ie, >15% reactive nuclei) was observed in 31 (17%) cases, and was associated with lower age, large tumor size, ductal morphology, high tumor grade, negative ER status, and lack of Bcl-2 immunoreactivity. In univariate analysis, the variables associated with short relapse-free survival (RFS) were large tumor size (P = .002), high histological grade (P = .01), high mitotic count (P = .03), and high Nottingham prognostic index (NPI) (P = .0002). In multivariate analysis (final mode)), only the NPI was of independent prognostic value concerning RFS.

Original languageEnglish
Pages (from-to)1149-1155
Number of pages7
JournalHuman Pathology
Issue number11
Publication statusPublished - 1996


  • Bcl-2
  • breast cancer
  • estrogen receptors
  • human
  • immunohistochemistry
  • p53 protein
  • survival analysis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Bcl-2 and p53 expression in node-negative breast carcinoma: A study with long-term follow-up'. Together they form a unique fingerprint.

Cite this